ArticleTranslational cancer research2026
Single-cell RNA sequencing identifies cancer-associated fibroblast marker genes for determining cancer subtypes in oral squamous cell carcinoma and predicting patient prognosis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) is an extremely aggressive cancer of which its progression and prognosis are strongly affected by cancer-associated fibroblast (CAF) and immunosuppression procedure. This study aimed to identify CAF marker genes through single-cell RNA sequencing (scRNA-seq) data and clarify the roles of CAF-related genes in tumor typing and disease prognosis prediction for OSCC patients. Methods: Gene expression data of OSCC patients were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. The differential expression of CAF genes was identified using the limma R package. Univariate Cox regression, least absolute shrinkage and selection operator (LASSO) Cox analysis, and multivariate Cox analysis were performed to construct a CAF-related prognostic signature. The accuracy of prediction performance was assessed by the time-dependent receiver operating characteristic (ROC) curve, Kaplan-Meier analysis, principal component analysis (PCA), decision curve analysis, calibration curve, and concordance index. Differences of tumor mutational burden, tumor-infiltrating immune cells, and response to immunotherapy between the high- or low-risk groups were investigated. Results: Our results showed that the CAF-high subtype exhibited poorer survival outcomes than the CAF-low subtype. The CAF-high subtype exhibited higher immune infiltration, stromal components, and immune escape potential than the CAF-low subtype. The CAF-high subtype OSCC patients demonstrated reduced sensitivity to immunotherapy than the CAF-low subtype. Conclusions: Our prognostic model could predict overall survival (OS) and the immunotherapy response of OSCC patients. These findings highlight the importance of targeting CAF in OSCC treatment and provide valuable insights into the tumor microenvironment (TME) heterogeneity and immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.